Key facts
- This page summarizes Alison Moore's Form 4 filing for Artiva Biotherapeutics, Inc. (ARTV).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 26 Jun 2025, 16:30.
Alison Moore - 24 Jun 2025 Form 4 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)
- Reporting relationship
- Director
- Issuer ticker
- ARTV
- Reported as of
- 24 Jun 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Jun 2025, 16:30:22 UTC
- Prior SEC filing
- 07 Feb 2025
- Next SEC filing
- 15 Oct 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Neha Krishnamohan, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Alison Moore filed Form 4 for Artiva Biotherapeutics, Inc. (ARTV) on 26 Jun 2025.
Change
- Previous filing in this sequence was filed on 07 Feb 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001754937
Primary reporting owner
MOORE ALISON
- Relationship
- Director
- Address
- C/O ARTIVA BIOTHERAPEUTICS, INC., 5505 MOREHOUSE DRIVE, SUITE 100, SAN DIEGO
- Signature
- /s/ Neha Krishnamohan, Attorney-in-Fact
- Signature date
- 26 Jun 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ARTV
transaction
Derivative
Director Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +13,750
- Change %
- Price
- $0.000000
- Shares after
- 13,750
- Date
- 24 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,750
- Exercise price
- $1.61
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares subject to the option will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting.